trending Market Intelligence /marketintelligence/en/news-insights/trending/CEWtgZ8MlmEG3-9A9jOJAg2 content esgSubNav
In This List

Oxford Immunotec, Qiagen settle patent infringement lawsuit

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Oxford Immunotec, Qiagen settle patent infringement lawsuit

Oxford Immunotec Global PLC and Qiagen NV settled a lawsuit regarding alleged patent infringement of Qiagen products.

The suit, filed in U.S. District Court for the District of Massachusetts in Boston, covered the Dutch company's QuantiFeron-TB gold and QuantiFeron-TB Gold Plus products.

U.K.-based Oxford granted Qiagen a royalty-free, nonexclusive license that extends to all current and future customers of the two Qiagen products in exchange for a one-time lump sum of $27.5 million.

Under the settlement, all pending claims between Oxford and Qiagen and the co-defendants were resolved. None of the parties admitted to any wrongdoing.

QuantiFeron-TB Gold is a diagnostic aid that detects infection caused by Mycobacterium tuberculosis, a type of bacteria that causes tuberculosis.